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The incidence of tuberculosis (TB) in South Africa (SA) – estimated 
to be the second highest incidence in the world according to 
the World Health Organization (WHO) – has reached epidemic 
proportions.1 The Western Cape has a TB incidence of 1 053/100 000 
per annum (M Poolman, personal communication). Inflammatory 
bowel disease (IBD) is increasing in many developing countries.2,3 
In Cape Town, a growing cohort of IBD patients are treated at the 
Groote Schuur Hospital (GSH) IBD clinic. 
Standard care includes treatment with immunosuppressive therapy 
such as corticosteroids, thiopurines (azathioprine and 6-mercaptopurine) 
and tumour necrosis factor-alpha (TNFα)-antagonists.4,5,6 The use of 
these drugs, alone and in combination, is associated with reactivation 
of latent TB.7 Increasingly, immunomodulators and TNFα-antagonists 
are used earlier and more aggressively to modify the natural course 
of IBD.8 Treatment protocols are based on experience in developed 
countries with a low TB prevalence,1 good healthcare infrastructure 
and patients knowledgeable about treatment side-effects. The high TB 
incidence in the Western Cape and the increasing emergence of IBD 
in SA and other developing countries pose management challenges. 
Treating IBD according to internationally accepted protocols may not 
be appropriate in developing countries. 
Recent data on TB incidence in IBD patients in the developing 
world are lacking. In Spain up to 12.5% of IBD patients have latent TB 
according to tuberculin skin testing (TST) results.9 In comparison, a 
study from a high TB burden area in SA found that among otherwise 
healthy adolescents about 50% had a TST >5 mm or a positive 
Quanti-FERON®-TB Gold In-Tube (QFT) assay.10 Data on TB in IBD 
patients in SA would be valuable for the development of appropriate 
treatment guidelines; we therefore studied the burden of TB in our 
cohort of IBD patients. 
Methods
We performed a retrospective analysis of the cohort of the 
GSH IBD clinic from 2002 to 2009. Baseline characteristics 
and TB data were obtained from an existing IBD database 
and from the National Health Laboratory Service database. 
Clinical records and chest X-rays were reviewed. Criteria for 
determining TB-positive patients included: (i) microbiological 
confirmation (smear positive for acid-fast bacilli or TB culture 
positive); (ii) histology consistent with TB; (iii) chest X-ray 
diagnosis of latent TB according to Centers for Disease Control 
and Prevention guidelines;11 and (iv) a clinical record history of 
treatment with anti-TB chemotherapy and associated resolution 
of symptoms suggestive of TB. Patients with confirmed IBD and 
a history of empiric treatment for intestinal TB without objective 
evidence of TB were not considered to be TB-positive. The 
use of immunosuppressive therapy was defined as any history 
of exposure to azathioprine, 6-mercaptopurine, methotrexate, 
infliximab and adalimumab. Data were not available on the use 
of corticosteroids. 
Data were analysed to identify possible risk factors for 
TB development in IBD. Statistical analyses were performed 
with STATA software (Release 11). Continuous variables were 
expressed as medians and interquartile ranges (IQRs) (non-
Gaussian distribution). Mann-Whitney tests were used to assess 
continuous variables, and chi-square or Fisher’s exact tests were 
used for categorical variables. Univariate analysis was performed 
initially for each variable. Multivariate logistic regression models 
were used for variables differing between the TB-positive versus 
negative groups with a significance level of p<0.1 and other 
possible confounders. A p-value ≤0.05 was considered to be 
significant. 
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Background. Potent immunosuppressive therapy is standard 
treatment for inflammatory bowel disease (IBD) but carries a risk 
of reactivating latent tuberculosis (TB). No data exist on the burden 
of TB in South African patients with IBD. 
Objective. To evaluate the burden of TB in IBD patients attending 
a large tertiary IBD clinic.
Methods. Data pertaining to patients attending the Groote 
Schuur Hospital IBD clinic were retrospectively analysed. Data were 
extracted from an existing IBD database, patient notes, the National 
Health Laboratory Services database and chest X-ray analysis. 
Results. Of 614 patients, 72 (11.7%) were diagnosed with TB; 40 
(55.6%) developed TB prior to the diagnosis of IBD. On regression 
analysis, coloured IBD patients were at increased risk for TB 
development (p=0.004, odds ratio (OR) 3.57, 95% confidence interval 
(CI) 1.49 - 8.56), as were patients with extensive Crohn’s disease 
(CD) compared with those with less extensive disease (p=0.001, OR 
2.84, 95% CI 1.27 - 6.33). No other risk factors, including the use of 
immunosuppressive agents, were identified for the development of TB.
Conclusions. Of over 600 patients, 12% had TB either before 
or after IBD diagnosis. The high rate of previous TB and positive 
association with ethnicity probably reflect the high burden of TB in 
a socio-economically disadvantaged community. We recommend 
that IBD patients should be screened actively and monitored for TB 
when immunosuppressive medications are used. 
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Results
Database entries were available for 614 of the 1 388 IBD patients 
who attended the clinic since its inception (Table 1), including 63% 
women, 66% coloured, 25% white, 5% black, and 4% Asian patients. 
The median age at IBD diagnosis was 32 years (IQR 24 - 43). Fifty-
three per cent of patients had Crohn’s disease (CD), 44% ulcerative 
colitis (UC) and 3% unclassified IBD (IBD-U). Seventy-seven per 
cent of patients with CD and 40% with UC were current or previous 
smokers. Only 25% received immunosuppressive therapy during 
management. The current practice is to test for HIV at diagnosis of 
IBD, but this was not standard policy until recently; the HIV status 
of the cohort was therefore not determined. 
Seventy-two (11.7%) patients were diagnosed with TB based 
on a history of treatment and clinical recovery in 26 (36.1%), 
microbiological evidence in 17 (23.6%), culture positivity for 
Mycobacterium TB in 10, a smear positive for acid-fast bacilli in 7, 
and chest X-ray changes in 16 (22.2%). Eleven (15.3%) patients had a 
history of TB treatment and chest X-ray changes consistent with TB, 
while 2 (2.8%) had histological changes suggestive of TB. 
In IBD patients diagnosed with TB, 40 (55.6%) developed TB 
before IBD diagnosis, 30 (41.7%) developed TB after IBD diagnosis 
and 2 (2.7%) acquired TB before and after IBD diagnosis. Sixty-
eight (94.4%) of the TB cases were of pulmonary origin, 2 of TB 
lymphadenitis, 1 of pleural TB and 1 of terminal ileal TB. 
Twelve patients (16.7%) had a history of immunosuppressive 
therapy; 7 (9.7%) were exposed within the 6 months before TB 
diagnosis; 6 received azathioprine and 1 received infliximab. 
On univariate analysis, patients with a history of TB were 
significantly more likely to be coloured (p=0.001, odds ratio (OR) 
2.8, 95% confidence interval (CI) 1.46 - 5.38), smokers (p=0.03,  OR 
1.85, 95%  CI 1.04 - 3.29) and to have ileocolitis as opposed to isolated 
small-bowel or colonic involvement (p=0.007, OR 2.42, 95% CI 1.24 - 
4.71). There were no statistical differences between the TB-positive 
and negative groups regarding age at diagnosis, gender, IBD subtype, 
or immunosuppression (Table 2). On multivariate analysis, only 
coloured race (p=0.004, OR 3.57, 95% CI 1.49 - 8.56) and ileocolitis 
(p=0.001,OR 2.84, 95% CI 1.27 - 6.33) were significantly associated 
with TB. 
Discussion
We report the first study of TB burden in an IBD population 
from a developing country. In more than 600 IBD patients, 12% 
had TB. In less than half of cases, TB was contracted after IBD 
diagnosis. Although disturbing, these figures represent Cape Town’s 
TB incidence, which is one of the highest in the world; the incidence 
of latent TB is greater than 50% in high-burden areas.1,7
Coloured patients with IBD were over 3 times more likely to 
develop TB, while white patients with IBD seemed to be relatively 
protected. This might have been attributed to socio-economic 
differences, but other causes, including genetic predisposition, need 
to be investigated. The study was not designed to account for 
this discrepancy. Furthermore, the traditionally socio-economically 
disadvantaged black cohort was not at increased risk of TB. It must 
be noted, however, that this cohort was small. This is a single-centre 
study; referral bias and the context of the Western Cape racial 
demographics must be considered. 
In patients with CD, extensive intestinal involvement – as opposed 
to isolated colitis or ileitis – was associated with an increased risk of 
TB. This is consistent with studies demonstrating that extensive CD 
is associated with poor outcomes.12
Although statistical significance was lost on multivariate analysis 
patients with a history of smoking were at slightly increased risk of 
developing TB (p=0.22, OR 1.48, 95% CI 0.79 - 2.79). These findings 
are compatible with smoking being a risk factor for acquiring TB.13
Although immunosuppressive therapy was not identified as a 
risk factor for the development of TB, there are several points to 
consider. The sample size was relatively small, and we could not 
account for steroid use, owing to the retrospective nature of the 
study. Corticosteroids pose a major risk of TB reactivation – in some 
studies, exceeding the risk posed by other immunosuppressives.14,15 
In our unit, access to TNFα-antagonists has been limited due to cost 
constraints; our data do not reflect their increasing use. 
The majority of TB cases that developed after IBD diagnosis 
were pulmonary in origin. This is not the usual presentation for 
immunosuppressive-associated reactivation of TB, which is typically 
extrapulmonary and disseminated.16 A possible explanation is that 
most of the TB cases represented incidental TB and not reactivation 
Table 1. Baseline characteristics of IBD patients 
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CD (n=303)
Never
Smoker (current or previous)
UC (n=239)
Never












IBD = inflammatory bowel disease; CD = Crohn’s disease;  UC = ulcerative colitis; IBD-U = 
inflammatory bowel disease unclassified. 
*Rounded to nearest whole number. 
†Azathioprine, 6-mercaptopurine, methotrexate and infliximab.
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caused by immunosuppressives. This is supported by the lack of 
association between immunosuppressive agents and TB in this study. 
We acknowledge that our inclusion criteria for the TB-positive 
group may not have been accurate. A history of TB treatment does 
not necessarily equate to TB infection; empiric therapy is often given 
without bacteriological confirmation. Misclassification bias may have 
resulted in falsely inflated numbers. 
Our data establish a comparator for further study. We recommend 
active screening of IBD patients for TB at diagnosis, before 
commencing immunosuppressive therapy according to international 
guidelines. With the combination of endemic TB and emerging 
IBD, more data are needed to develop appropriate guidelines for the 
developing world.
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IBD = inflammatory bowel disease (IBD); CD = Crohn’s disease; UC = ulcerative colitis (UC); IBD-U =  inflammatory bowel disease unclassified.
